OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
US-2016347837-A1 · Dec 1, 2016 · US
Fc variants with increased affinity for FcγRIIc
US10584176B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10584176-B2 |
| Application number | US-201816138605-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 21, 2018 |
| Priority date | Mar 3, 2003 |
| Publication date | Mar 10, 2020 |
| Grant date | Mar 10, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
First claim
Opening claim text (preview).
We claim: 1. A nucleic acid encoding a protein comprising an Fc variant of a parent Fc polypeptide, wherein the Fc variant comprises amino acid substitutions 239D, 332E and 330L, and numbering is according to the EU index. 2. The nucleic acid of claim 1 , wherein the parent Fc polypeptide is human IgG1. 3. The nucleic acid of claim 1 , wherein the protein is an antibody. 4. The nucleic acid of claim 3 , wherein the antibody is selected from the group consisting of a human antibody, a humanized antibody, and a chimeric antibody. 5. The nucleic acid of claim 1 , wherein the protein is an Fc fusion protein. 6. An expression vector comprising the nucleic acid of claim 1 . 7. A host cell comprising the nucleic acid of claim 1 . 8. A host cell comprising the expression vector of claim 6 . 9. A method of making a protein comprising: a) culturing the host cell of claim 7 under conditions wherein the protein is expressed; and b) recovering the protein. 10. A method of making a protein comprising: a) culturing the host cell of claim 8 under conditions wherein the protein is expressed; and b) recovering the protein.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
against receptors for growth factors, growth regulators · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Glycosylation, sialylation, or fucosylation · CPC title
Internalization into the cell · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10584176B2 cover?
- The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
- Who is the assignee on this patent?
- Xencor Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2893. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).